Rationale for targeted therapies in hepatocellular carcinoma

Targeted Oncology

Volumn 3, Issue 2, 2008, Pages 81-85

  Faivre, Sandrine ^a   Dreyer, Chantal ^a   El Maalouf, Ghassan ^a   Sablin, Marie Paule ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Angiogenesis; EGFR; IGF 1R; MTOR; Rapamycin; Tyrosine kinase inhibitors

Indexed keywords

EID: 42449088069     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-008-0079-4     Document Type: Article

References (26)

1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterol 132:2557-2576
2. Llovet J, Ricci S, Mazzaferro V et al (2007) Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma. J Clin Oncol (2007 ASCO Annual Meeting Proceedings) 25(18S):LBA1
3. Abou-alfa JK, Schwartz L, Ricci S et al (2007) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300
4. Faivre SJ et al (2007) Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol Abstract 3546
5. Faivre S et al (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745
6. Semela D et al (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41:864-880
7. Moon EJ et al (2004) Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1a. FASEB J 18:382-384
8. Yoshiji H et al (1999) KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30:1179-1186
9. Marzullo A et al (1998) Angiogenesis in hepatocellular carcinoma: an experimental study in the chick embryo chorioallantoic membrane. Int J Oncol 13:17-21
10. Yoshiji H et al (1998) Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28:1489-1496
11. Yamaguchi R et al (2000) Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 7:725-729
12. Shimamura T et al (2000) Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 15:640-646
13. Mitsuhashi N et al (2003) Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37:1105-1113
14. Liu Y et al (2005) Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 65:3691-3699
15. Giannelli G et al (2006) ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol 71:479-485
16. Liu L et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, induces tumor cell apoptosis in hepatocellular carcinoma moded PLC/PRF/5. Cancer Res 66:11851-11858
17. Schiffer E et al (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41:307-314
18. Zhu AX et al (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110:581-589
19. Thomas MB et al (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059-1067
20. Rogler CE et al (1994) Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 269:13779-13784
21. Scharf JG et al (2003) The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 35:685-693
22. Desbois-Mouthon C et al (2006) Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119:2557-2566
23. Faivre S et al (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671-688
24. Sahin F et al (2004) mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10:8421-8425
25. Semela D et al (2007) Vascular remodelling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46:840-848
26. Rizell M, Cahlin C, Friman S et al (2007) Sirolimus retards growth of hepatocellular cancer. Proc Fifth International Meeting on Hepatocellular Carcinoma: Eastern and Western Experiences January 11-13, 2007, held in MD Anderson, Houston, Texas, Poster #3